Cargill Inc.

Merial Limited

Newport Laboratories

Benjamin Matthew Hause

Aristos Aristidou

Catherine Asleson Dundon

Brian Jeffrey Rush

Pirkko Suominen

Kari Koivuranta

Thomas W McMullin

Kevin Roberg-Perez

Russell F Bey

Randy R Simonson

Pim Van Hoek

Kamesh Reddy Sirigireddy

Pirrko Suominen

Thomas William McMULLIN

Emily A Collin

Matthew Miller

Randy S Simonson

Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the generaor. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.

Yeast cells having disrupted pathway from dihydroxyacetone phosphate to glycerol

Fermentation process using yeast cells having disrupted pathway from dihydroxyacetone phosphate to glycerol

This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.

Attenuated swine influenza vaccines and methods of making and use thereof

The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides.

Rotavirus subunit vaccines and methods of making and use thereof

A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus.

Influenza C virus and vaccine

Yeast cells having an exogenous lactate dehydrogenase gene ae modified by reducing L- or D-lactate:ferricytochrome c oxidoreductase activity in the cell. This leads to reduced consumption of lactate by the cell and can increase overall lactate yields in a fermentation process. Cells having the reduced L- or D-lactate:ferricytochrome c oxidoreductase activity can be screened for by resistance to organic acids such as lactic or glycolic acid.

Lactic acid-producing yeast cells having nonfunctional L- or D-lactate:ferricytochrome C oxidoreductase cells

Growing community of inventors

Currie, MN, United States of America

Benjamin Matthew Hause